PURPOSE: To evaluate the feasibility of dose-painting intensity-modulated radiation therapy (DP-IMRT) with a hypofractionated regimen to treat nasopharyngeal carcinoma (NPC) with concomitant toxicity reduction. METHODS AND MATERIALS: From October 2002 through April 2007, 25 newly diagnosed NPC patients were enrolled in a prospective trial. DP-IMRT was prescribed to deliver 70.2 Gy using 2.34-Gy fractions to the gross tumor volume for the primary and nodal sites while simultaneously delivering 54 Gy in 1.8-Gy fractions to regions at risk of microscopic disease. Patients received concurrent and adjuvant platin-based chemotherapy similar to the Intergroup 0099 trial. RESULTS: Patient and disease characteristics are as follows: median age, 46; 44% Asian; 68% male; 76% World Health Organization III; 20% T1, 52% T2, 16% T3, 12% T4; 20% N0, 36% N1, 36% N2, 8% N3. With median follow-up of 33 months, 3-year local control was 91%, regional control was 91%, freedom from distant metastases was 91%, and overall survival was 89%. The average mean dose to each cochlea was 43 Gy. With median audiogram follow-up of 14 months, only one patient had clinically significant (Grade 3) hearing loss. Twelve percent of patients developed temporal lobe necrosis; one patient required surgical resection. CONCLUSIONS: Preliminary findings using a hypofractionated DP-IMRT regimen demonstrated that local control, freedom from distant metastases, and overall survival compared favorably with other series of IMRT and chemotherapy. The highly conformal boost to the tumor bed resulted low rates of severe ototoxicity (Grade 3-4). However, the incidence of in-field brain radiation necrosis indicates that 2.34 Gy per fraction is not safe in this setting.
PURPOSE: To evaluate the feasibility of dose-painting intensity-modulated radiation therapy (DP-IMRT) with a hypofractionated regimen to treat nasopharyngeal carcinoma (NPC) with concomitant toxicity reduction. METHODS AND MATERIALS: From October 2002 through April 2007, 25 newly diagnosed NPCpatients were enrolled in a prospective trial. DP-IMRT was prescribed to deliver 70.2 Gy using 2.34-Gy fractions to the gross tumor volume for the primary and nodal sites while simultaneously delivering 54 Gy in 1.8-Gy fractions to regions at risk of microscopic disease. Patients received concurrent and adjuvant platin-based chemotherapy similar to the Intergroup 0099 trial. RESULTS:Patient and disease characteristics are as follows: median age, 46; 44% Asian; 68% male; 76% World Health Organization III; 20% T1, 52% T2, 16% T3, 12% T4; 20% N0, 36% N1, 36% N2, 8% N3. With median follow-up of 33 months, 3-year local control was 91%, regional control was 91%, freedom from distant metastases was 91%, and overall survival was 89%. The average mean dose to each cochlea was 43 Gy. With median audiogram follow-up of 14 months, only one patient had clinically significant (Grade 3) hearing loss. Twelve percent of patients developed temporal lobe necrosis; one patient required surgical resection. CONCLUSIONS: Preliminary findings using a hypofractionated DP-IMRT regimen demonstrated that local control, freedom from distant metastases, and overall survival compared favorably with other series of IMRT and chemotherapy. The highly conformal boost to the tumor bed resulted low rates of severe ototoxicity (Grade 3-4). However, the incidence of in-field brain radiation necrosis indicates that 2.34 Gy per fraction is not safe in this setting.
Authors: S L Wolden; M J Zelefsky; M A Hunt; K E Rosenzweig; L M Chong; D H Kraus; D G Pfister; S A Leibel Journal: Int J Radiat Oncol Biol Phys Date: 2001-04-01 Impact factor: 7.038
Authors: Anne W M Lee; Dora L W Kwong; Sing Fai Leung; Stewart Y Tung; Wai Man Sze; Jonathan S T Sham; Peter M L Teo; To Wai Leung; Po Man Wu; Rick Chappell; Lester J Peters; John F Fowler Journal: Int J Radiat Oncol Biol Phys Date: 2002-05-01 Impact factor: 7.038
Authors: Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang Journal: J Clin Oncol Date: 2009-06-29 Impact factor: 44.544
Authors: Michael K M Kam; Ricky M C Chau; Joyce Suen; Peter H K Choi; Peter M L Teo Journal: Int J Radiat Oncol Biol Phys Date: 2003-05-01 Impact factor: 7.038
Authors: Stefan Janssen; Christoph Glanzmann; Bita Yousefi; Karl Loewenich; Gerhard Huber; Stephan Schmid; Gabriela Studer Journal: Mol Clin Oncol Date: 2015-05-04
Authors: Jeremy Setton; James Han; Danita Kannarunimit; Yen-Ruh Wuu; Stephen A Rosenberg; Carl DeSelm; Suzanne L Wolden; C Jillian Tsai; Sean M McBride; Nadeem Riaz; Nancy Y Lee Journal: Oral Oncol Date: 2015-12-07 Impact factor: 5.337
Authors: Ladan Saleh-Ebrahimi; Felix Zwicker; Marc W Muenter; Marc Bischof; Katja Lindel; Juergen Debus; Peter E Huber; Falk Roeder Journal: Radiat Oncol Date: 2013-01-24 Impact factor: 3.481